skip to Main Content

IMPORTANT: The Bladder Cancer Canada discussion forum is not a substitute for professional medical advice or treatment. The opinions & contents in this forum is for information only and is not reviewed by medical professionals. They are experiences & opinions of patient members like you, and is NOT intended to represent the best or only approach to a situation. Always consult your physician and do not rely solely on the information in this site when making decisions about your health.

Homepage – Forum Forums Muscle Invasive Bladder Cancer Do you have Stage II or higher bladder cancer?

Viewing 1 post (of 1 total)
  • Author
  • #39246
    Jack Moon

    Bladder Cancer Canada is looking for patients who fit these criteria to complete a 20-minute survey about their views on potential new treatments for metastatic bladder cancer.

    It is critical to also survey a subgroup of patients who have specific experience with avelumab (Bavencio) as a first-line maintenance treatment for locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy.

    You do not need to live in Canada to respond to this survey.

    Participate in Survey
    DEADLINE:       Respond by Sept. 16, 2020

    Why is your participation important?

    The pan-Canadian Oncology Drug Review (pCODR) makes recommendations about whether provincial health plans should pay for new cancer drugs. pCODR will soon be reviewing the use of avelumab to treat stage IV (locally advanced or metastatic urothelial carcinoma), in patients who have previously received platinum-based chemotherapy. Bladder Cancer Canada will be making a submission to ensure that patient voices are represented and considered during the review process.


    View this information on the pCODR website here.

    Questions can be addressed to or by calling 1-866-674-8889.

    Privacy Policy: To ensure patient privacy and confidentiality, individual responses will not be identifiable. It is important to note that selected quotations may be used for the final submission to government agencies without reference to patient name or any other information that could lead to identifying the patient.


Viewing 1 post (of 1 total)
  • You must be logged in to reply to this topic.
Back To Top